Research Topics
| H B NewtonSummaryAffiliation: The Ohio State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Neurological complications of chemotherapy to the central nervous systemHerbert B Newton
Department of Nedurology, Ohio State University Medical Center, Columbus, OH, USA
Handb Clin Neurol 105:903-16. 2012..The retinoid drugs are known to cause severe headaches at high doses. l-Asparaginase can induce an encephalopathy syndrome, as well as cerebrovascular complications such as stroke...- Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-upH B Newton
Division of Neuro Oncology, Dardinger Neuro oncology Center, Department of Neurology, Ohio State University Medical Center, Columbus, Ohio 43210, USA
Br J Neurosurg 18:495-9. 2004.... - Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycleHerbert B Newton
Dardinger Neuro oncology Center, Department of Neurology, The Ohio State University Hospitals, 465 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Expert Rev Anticancer Ther 5:355-78. 2005..Further development of targeted therapies designed to modulate apoptosis and the cell cycle, and evaluation of these new agents in clinical trials, will be needed to improve survival and quality of life for patients with brain tumors... - Intra-arterial chemotherapy of primary brain tumorsHerbert B Newton
Dardinger Neuro Oncology Center and Division of Neuro Oncology, Department of Neurology, The Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, 1654 Upham Drive, Columbus, OH 43210, USA
Curr Treat Options Oncol 6:519-30. 2005..Further clinical studies will be needed to determine the appropriate role for IA chemotherapy in the treatment of primary brain tumors... - Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patientsHerbert B Newton
Dardinger Neuro Oncology Center and Division of Neuro Oncology, Department of Neurology, Ohio State University Medical Center, Columbus, Ohio 43210, USA
J Neurooncol 78:99-102. 2006..LEV was very effective and well tolerated in brain tumor patients with seizures, and should be considered for add-on therapy to current AEDs, or as a substitute anti-convulsant for monotherapy... - Incidence of infusion plan alterations after angiography in patients undergoing intra-arterial chemotherapy for brain tumorsHerbert B Newton
Division of Neuro Oncology and Dardinger Neuro Oncology Center, Department of Neurology, Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, 465 Means Hall, 1654 Upham Drive, Columbus, Ohio, USA
J Neurooncol 78:157-60. 2006..In our series, the angiography results necessitated an alteration of the infusion plan in 6.4% of the patient cohort... - Advances in strategies to improve drug delivery to brain tumorsHerbert B Newton
Dardinger Neuro oncology Center, Division of Neuro Oncology, 465 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Expert Rev Neurother 6:1495-509. 2006..The most commonly used vectors are peptidomimetic antibodies to endothelial receptors, such as the transferrin and insulin receptors... - Brain tumor imaging and cancer management: the neuro-oncologists perspectiveHerbert B Newton
Division of Neuro Oncology, Department of Neurology, Dardinger Neuro oncology Center, The Ohio State University Medical Center, Columbus, OH 43210, USA
Top Magn Reson Imaging 17:127-36. 2006..New magnetic resonance techniques such as magnetic resonance spectroscopy, diffusion-weighted imaging, and perfusion-based imaging methods will also be discussed where applicable... - Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumorsHerbert B Newton
Dardinger Neuro Oncology Center and Division of Neuro Oncology, Department of Neurology, Ohio State University Medical Center, and James Cancer Hospital and Solove Research Institute, Columbus, OH, USA
J Neurooncol 84:293-6. 2007..LEV was very effective and well tolerated in MBT patients with seizures and should be considered for add-on therapy or as a substitute AED for monotherapy... - Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumorsHerbert B Newton
Dardinger Neuro oncology Center, Division of Neuro Oncology, 465 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Curr Opin Investig Drugs 8:1009-21. 2007.... - Glioblastoma multiformeHerbert B Newton
Herbert B Newton, MD Dardinger Neuro Oncology Center, Department of Neurology, Ohio State University Medical Center, 465 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Curr Treat Options Neurol 10:285-94. 2008..Molecular therapy, with drugs targeting growth factor receptors and critical signal transduction pathway mediators, is also under active investigation... - Aggressive papillary glioneuronal tumor: case report and literature reviewH B Newton
Dardinger Neuro oncology Center, Ohio State University Medical Center and James Cancer Hospital, Columbus, OH, USA
Clin Neuropathol 27:317-24. 2008..This patient demonstrates that PGNT may, in rare cases, display an aggressive clinicopathologic phenotype that requires a therapeutic approach more consistent with a high-grade glioma... - Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathwayHerbert B Newton
Dardinger Neuro oncology Center, Department of Neurology, Ohio State University Hospitals, 465 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Expert Rev Anticancer Ther 5:177-91. 2005..Further development of targeted therapies designed to restore or enhance p53 function, and evaluation of these new agents in clinical trials, will be needed to improve survival and quality of life for patients with brain tumors... - Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasivenessHerbert B Newton
Dardinger Neuro oncology Center, Department of Neurology, Ohio State University Hospitals, 465 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Expert Rev Anticancer Ther 4:803-21. 2004..Further development of targeted therapies designed to inhibit tumor infiltration, and evaluation of these new agents in clinical trials, will be needed to improve survival and quality of life for patients with brain tumors... - Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesisHerbert B Newton
Dardinger Neuro oncology Center, Department of Neurology, Ohio State University Hospitals, 465 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Expert Rev Anticancer Ther 4:105-28. 2004..Further development of targeted therapies and evaluation of these new agents in clinical trials will be needed to improve survival and quality of life of patients with brain tumors... - Novel chemotherapeutic agents for the treatment of brain cancerH B Newton
Department of Neurology, The Ohio State University Hospitals, 465 Means Hall, 1654 Upham Drive, Columbus, Ohio 43210, USA
Expert Opin Investig Drugs 9:2815-29. 2000..It is hoped that this research will lead to new therapeutic targets for drug design and development. In addition, new strategies must be developed to overcome the problem of chemotherapy resistance... - Hydroxyurea chemotherapy for unresectable or residual meningiomaH B Newton
Department of Neurology, The Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, USA
J Neurooncol 49:165-70. 2000..Hydroxyurea appears to have modest activity against meningiomas and should be considered in patients with unresectable tumors or large residual tumors following surgical resection... - Neurologic complications of scuba divingH B Newton
Department of Neurology, Ohio State University Hospitals, Columbus 43210, USA
Am Fam Physician 63:2211-8. 2001..Common signs and symptoms include vertigo, thoracic myelopathy with leg weakness, confusion, headache and hemiparesis. Other diving-related neurologic complications include headache and oxygen toxicity... - Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumorsH B Newton
Department of Neurology, The Ohio State University, Columbus 43210, USA
Ann Pharmacother 33:816-32. 1999..To briefly review the clinical presentation and diagnosis of patients with primary brain tumors, followed by an in-depth survey of the pertinent pharmacotherapy... - Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastomaH B Newton
Department of Neurology, The Ohio State University Hospitals, 465 Means Hall, 1654 Upham Drive, Columbus, Ohio 43210, USA
Expert Opin Investig Drugs 10:2089-104. 2001..Further clinical trials will be needed to evaluate the activity of these new drugs and determine their role in the treatment plan of patients with medulloblastoma... - Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case reportH B Newton
Department of Neurology, The Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
J Neurooncol 55:179-84. 2001..The effectiveness of carboplatin may be improved if administered by the IA route... - Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomasHerbert B Newton
Department of Neurology, The Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, Columbus 43210, USA
J Neurooncol 56:79-86. 2002..Two patients had embolic complications. Although these are preliminary results, IA carboplatin and IV etoposide have modest activity against recurrent and progressive non-GBM gliomas and warrants further study... - Chemotherapy for the treatment of metastatic brain tumorsHerbert B Newton
Division of Neuro Oncology, Department of Neurology, Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, 1654 Upham Drive, Columbus, Ohio 43210, USA
Expert Rev Anticancer Ther 2:495-506. 2002.... - Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumorsHerbert B Newton
Division of Neuro Oncology, Department of Neurology, The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, OH, USA
J Neurooncol 61:35-44. 2003..Angiographic complications were rare. Although these are preliminary results, IA carboplatin and IV etoposide is safe and well tolerated, appears to be active against brain metastases, and warrants further study... - Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathwaysHerbert B Newton
Dardinger Neuro oncology Center, Department of Neurology, Ohio State University Hospitals, Columbus 43210, USA
Expert Rev Anticancer Ther 3:595-614. 2003..Further development of targeted therapies and evaluation of these new agents in clinical trials will be needed to improve survival and quality of life of patients with brain tumors... - Prevalence and rupture rate of cerebral aneurysms discovered during intra-arterial chemotherapy of brain tumorsE C Bourekas
Section of Neuroradiology, Department of Neurology, Ohio State University College of Medicine and Public Health, Columbus, USA
AJNR Am J Neuroradiol 27:297-9. 2006..In our patient population, there was no indication that an incidental aneurysm was reason to preclude or delay the use of IA chemotherapy... - Neurological decompression illness and hematocrit: analysis of a consecutive series of 200 recreational scuba diversH B Newton
Division of Neuro Oncology and Dardinger Neuro Oncology Center, Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
Undersea Hyperb Med 35:99-106. 2008..Hematocrit values of 48 or higher were correlated with the presence of motor weakness and severity of sensory symptoms in female divers. The hematocrit did not correlate with neurological DCI in male divers... - Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3Michal O Nowicki
Dardinger Laboratory for Neuro oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, OH 43210, USA
Neuro Oncol 10:690-9. 2008..These data outline previously unidentified pathways and inhibitors that may be useful for the development of novel anti-invasive therapeutics for the treatment of brain tumors... - Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruptionMarcus W C Macnealy
College of Medicine, The Ohio State University Medical Center, 370 West 9th Ave, Columbus, OH 43210, USA
J Neurooncol 90:329-33. 2008..Following six cycles of rituximab and CHOP treatment, she is presently in complete remission. IA methotrexate and reversible osmotic BBBD without radiation therapy may be an effective therapy for treating PML... - Hydroxyurea chemotherapy in the treatment of meningiomasHerbert B Newton
Dardinger Neuro Oncology Center and Division of Neuro Oncology, Department of Neurology, The Ohio State University Medical Center, Columbus, Ohio 43210, USA
Neurosurg Focus 23:E11. 2007..However, the results are conflicting and a few clinical trials did not show positive results. Further clinical trials with larger patient cohorts and longer follow-up periods will be necessary to confirm the activity of hydroxyurea... - Neurological manifestations of decompression illness in recreational divers - the Cozumel experienceH B Newton
Division of Neuro Oncology, Ohio State University Medical Center and James Cancer Hospital, Columbus, Ohio, USA
Undersea Hyperb Med 34:349-57. 2007..001). Neurological manifestations are common in recreational divers treated for DCI. Neurological DCI and paresthesias are more likely to occur in younger and less experienced divers... - MicroRNAs and glioblastoma; the stem cell connectionJ Godlewski
Dardinger Laboratory for Neuro oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA
Cell Death Differ 17:221-8. 2010..This encourages the idea that certain miRs allow continued tumor growth through the suppression of differentiation and the maintenance of the stem cell-like properties of tumor cells. These concepts will be explored in this article... - Symptom management and supportive care of the patient with brain metastasesHerbert B Newton
Dardinger Neuro oncology Center, Department of Neurology, Ohio State University Hospitals, Columbus, OH 43210, USA
Cancer Treat Res 136:53-73. 2007..Appropriate management of these supportive aspects of patient care will improve overall quality of life and allow the patient and family to more easily concentrate on treatment... - Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewalJakub Godlewski
Dardinger Laboratory for Neuro oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University Medical Center and James Comprehensive Cancer Center, Columbus, Ohio 43210
Cancer Res 68:9125-30. 2008.... - Visualization of microvascularity in glioblastoma multiforme with 8-T high-spatial-resolution MR imagingGregory A Christoforidis
Department of Radiology, The Ohio State University Medical Center, 168 Means Hall, 1654 Upham Drive, Columbus, OH 43221, USA
AJNR Am J Neuroradiol 23:1553-6. 2002..Preliminary data indicate that 8-T high-spatial-resolution MR imaging may enable the identification of areas of abnormal microvascularity in glioblastoma multiforme that are not visible with other routine clinical techniques... - Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative OncolStuart A Grossman
1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
J Clin Oncol 21:1485-91. 2003..The control arm consisted of radiation with standard adjuvant BiCNU... - Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 104:1478-86. 2005..The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)... - Central nervous system cancers: Clinical Practice Guidelines in OncologySteven S Brem
J Natl Compr Canc Netw 3:644-90. 2005 - Central nervous system cancersSteven S Brem
H Lee Moffitt Cancer Center and Research Institute
J Natl Compr Canc Netw 6:456-504. 2008